ORD 22246/2025

—·EP2493466: NOVEL ANTITUMORAL USE OF CABAZITAXEL

Case details: Status
—
Action
Procedural application
Category
Case Management Orders
Parties: Claimants
Sanofi SA
Sanofi Winthrop Industrie
Sanofi-Aventis Deutschland GmbH
Sanofi Belgium
Sanofi-Aventis GmbH
Sanofi S.r.l.
Sanofi B.V.
Sanofi - Produtos Farmaceuticos Lda
Sanofi AB
Sanofi A/S
Reps: Frédéric Chevallier (McDermott Will & Schulte)
Respondents
Accord Healthcare S.L.U.
Accord Healthcare GmbH (AT)
Accord Healthcare B.V.
Accord Healthcare GmbH (DE)
Accord Healthcare Italia Srl
Accord Healthcare, Unipessoal Lda.
Accord Healthcare AB
STADAPHARM GmbH
STADA Arzneimittel AG
STADA Nordic ApS
Reddy Pharma SAS
betapharm Arzneimittel GmbH
Dr Reddy's Srl
Zentiva France
Zentiva Pharma GmbH
Zentiva, k.s.
Reps: Jules Fabre (Taylor Wessing); Daniel Hoppe (Bonabry); Christian Meyer (Maiwald); Anja Lunze (Taylor Wessing)
Division: Munich LD
Judges: Matthias Zigann · Presiding judge and judge-rapporteur
Technology: Pharmaceutical & Medical
Language: —
First decided: Jul 17, 2025

Decisions

2025-07-17
Generic Order
The Local Division Munich issued a case management order following an interim conference in parallel infringement proceedings by Sanofi against multiple generics manufacturers (Accord, STADA, Reddy, Zentiva) concerning EP 2 493 466, noting EPO BoA uphold of the patent, scheduling the oral hearing for October 2025, and addressing expert evidence and confidentiality of interim damages calculations.
Legal issues:Case management post-interim conference (R.105.5 RoP)EPO BoA validity decisionExpert evidence – hot tubbingConfidentiality of interim damages calculationsParallel French national invalidity proceedings

Documents